| Literature DB >> 31929762 |
Chun-Bing Chen1,2,3,4,5,6, Wan-Chun Chang1, Ming-Ying Wu1,4, Tzu-Yang Kao1, Ying-Wen Wang1, Chuang Wei Wang1,2,3, Chi-Ju Chen7, Wen-Hung Chung1,2,3,4,6,8, Shih-Chi Su1,2.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Current studies have suggested that the pathobiology of drug-mediated SJS/TEN involves a dysregulation of cellular immunity with overwhelming activation of cytotoxic T lymphocytes. The canonical Wnt signaling pathway plays important roles in T cell development and activation, which may provide potential avenues for alleviating dysregulated immunity in SJS/TEN. In this study, we aimed to assess the implication of Wnt signaling in drug-reactive T cells in SJS/TEN. We showed downregulation of Wnt signaling components, including T cell factor 1 (TCF-1)/lymphoid enhancer binding factor 1 (LEF-1) transcription factors, in SJS/TEN patients, suggesting that canonical Wnt signaling is regulated during cytotoxic T cell responses in SJS/TEN. Further analyses demonstrated that engagement of the T cell receptor by antigen encounter and treatment of a prognostic marker of SJS/TEN, IL-15, in vitro led to the downregulation of LEF-1 and TCF-1 expression in CD8+ T cells. Enhancement of Wnt signaling by adding the Wnt activators attenuated ex vivo activation of drug-specific T cells from SJS/TEN patients, indicating a functional involvement of Wnt signaling in the pathomechanism of SJS/TEN. These findings provide additional insight into the immunopathogenesis and therapeutic intervention of this devastating condition. © The author(s).Entities:
Keywords: Stevens-Johnson syndrome (SJS); T cell factor-1 (TCF-1); Wnt; cytotoxic T lymphocyte (CTL); lymphoid enhancer binding factor 1 (LEF-1).; toxic epidermal necrosis (TEN)
Year: 2020 PMID: 31929762 PMCID: PMC6949146 DOI: 10.7150/ijbs.32331
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Demographic and clinical characteristics of SJS/TEN patients
| Demographic data | SJS/TEN (n=25) |
|---|---|
| 52.5 ± 18.7 (3-81) | |
| 9:16 | |
| Erythema | 56.5± 26.7 (10-100) |
| Blister or detachment | 30.9± 22.9 (1-80) |
| Ocular | 20 (80.0) |
| Oral | 25 (100.0) |
| Genital | 18 (72.0) |
| Hepatitis a | 7 (28.0) |
| Acute kidney injury b | 6 (24.0) |
| Gastrointestinal bleeding | 6 (24.0) |
| Pneumonitis, pneumonia, or bronchiolitis obliterans | 4 (16.0) |
| Eosinophilia c | 6 (24.0) |
| Leukocytosis d | 4 (16.0) |
| Leukopenia e | 9 (36.0) |
| Atypical lymphocytosis f | 16 (64.0) |
| Thrombocytopeniag | 7 (28.0) |
| 5 (20.0) | |
| 13 (42.0) | |
| 5 (20.0) | |
| Malignancy | 2 |
| Chronic kidney disease | 4 |
| Chronic liver disorder | 3 |
| Diabetes | 3 |
| Hypertension | 9 |
| Gouty | 5 |
| Epilepsy/Neuralgia | 5 |
| Rheumatoid arthritis | 1 |
| Anticonvulsants i | 8 |
| Antibiotics j | 7 |
| Allopurinol | 4 |
| Chlorzoxazone | 1 |
| Dapsone | 1 |
| NSAIDs | 1 |
| PPI | 1 |
| Sulfasalazine | 2 |
SD, standard deviation; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; TBSA, total body surface area; NSAIDs, Non-Steroidal Anti-Inflammatory Drug; PPI, proton pump inhibitor.
a Values were 2 times greater than normal for glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, or total bilirubin.
b The value of creatinine was 1.5 times greater than the normal value range (0.4-1.5 mg%) after drug intake.
c Eosinophils > 0.7 × 109/L, or > 5%, or >10% if leukocyte < 4.0 × 109/L.
d The leukocyte count was greater than 11,000/μL.
e The leukocyte count was less than 3,500/μL.
f Abnormal lymphocytes present in blood.
g The platelet count was lower than 150,000/μL.
h Patients had a body temperature greater than 38.5°C.
i Carbamazepine, lamotrigine, phenobarbital, and phenytoin.
i Cephalexin, flomocef, moxifloxacin, levofloxacin, and vancomycin.
Figure 1Expression of Wnt signaling components is regulated in SJS/TEN and drug-specific T cell activation. (A) Gene expression analyses of Wnt signaling components in blister cells (BCs) and PBMCs of subjects with SJS/TEN. mRNA expression of LEF1, TCF1, LRP5, and LRP6 was determined by real-time PCR. The respective mRNA levels were compared among the blister cells (n=5) and PBMCs (n=5) from subjects with SJS/TEN at active stage and control PBMCs from healthy donors (HD) (n=3). (B) Gene expression of Wnt signaling components in drug-activated T cells from SJS/TEN patients. PBMCs obtained from three SJS patients at active stage were cultured in RPMI1640 medium and stimulated without (Control) and with the culprit drugs (MED), Solaxin, carbamazepine, and vancomycin, respectively. After 7 days, the mRNA expression of LEF1, TCF1, LRP5, and LRP6 in drug-sensitive T cells, which were determined with the stimulation index (SI, calculated by the level of secreted granulysin of stimulated to unstimulated cultures) greater than 2, was measured by real-time PCR. *p <0.05; ** p <0.01; ***p <0.001; n.s, not significant; two-sided Student's t-test.
Figure 2Intracellular LEF1 and TCF1 protein expression in CD8 T cell subsets of SJS/TEN patients. TCF1 and LEF1 protein expression was detected in CD8 T cell subsets by intracellular FACS staining. Black line histograms indicate TCF1 (A) or LEF1 (B) staining at the active stage of disease course, and color line histograms represent staining at the recovered stage. Representative flow cytometry plots show the expression levels of TCF1 (A) or LEF1 (B) in peripheral CD8 T cells of SJS/TEN patients. A representative example from one SJS/TEN patient is shown from four individual SJS/TEN patients. (C-D) The fraction of TCF1high CD8 T cells and LEF1high CD8 T cells populations are increased at the recovery stage comparing with that at the active stage by intracellular FACS staining though no statically significance (p=0.18 and p=0.15, respectively).
Figure 3Endogenous Wnt inhibitors associated with SJS/TEN. (A) Serum levels of DKK1, SOST, WIF1, and Wnt3a were examined in 10 patients with SJS/TEN and 11 healthy donors (HD) by ELISA. (B) The levels of DKK1, SOST, WIF1, and Wnt3a in blister fluid of 9 TEN patients and 11 burn patients were measured by ELISA. * p< 0.05; ** p< 0.01; *** p< 0.001; two-sided Student's t-test.
Figure 4IL-15 contributes to the attenuation of Wnt signaling in CD8+ T cells. (A) TCF1 protein expression was detected in CD8+ T cell subsets by intracellular FACS staining after PBMCs were treated with cytokines indicated for 24 hr. Representative flow cytometry plots were shown from one of three independent experiments. (B-E) We observed a significant decrease in the portion of TCF1high CD8 T cells in PBMCs from normal subjects that were treated with IL-15, but not with IL-6, IL-8, or SDF-1(stromal cell-derived factor-1, used as a non-SJS-related cytokine). * p< 0.05; two-sided Student's t-test.
Figure 5Drug-specific TCR engagement attenuates the Wnt signal transduction in SJS/TEN. PBMCs of a carbamazepine (CBZ)-induced SJS/TEN patient were stimulated with the culprit drug (CBZ) or a tolerant drug (phenytoin, PHT) for 7 days. Levels of LEF1 and TCF1 protein expression were detected in CD8+ T cell subsets by intracellular FACS staining. Representative flow cytometry plots were shown from one of five independent experiments.
Figure 6Activation of Wnt signaling attenuates activation of drug-specific T cells. PBMCs of a carbamazepine (CBZ)- (A) or Ketoprofen-sensitive (B) SJS patient were obtained from the heparinized blood by density centrifugation on Ficoll-Hypaque and stimulated with and without the culprit drugs in the absence or presence of different concentrations of Wnt signaling activator including LiCl (A) or SB216763 (B). After 7 days, the stimulation index (SI) will be calculated by the level of secreted granulysin of stimulated to unstimulated cultures. * p< 0.05; two sided Student's t-test.